Home/Pipeline/DCVax®-L

DCVax®-L

Glioblastoma (GBM)

Phase 3Active

Key Facts

Indication

Glioblastoma (GBM)

Phase

Phase 3

Status

Active

Company

Northwest Biotherapeutics

About Northwest Biotherapeutics

Northwest Biotherapeutics is a pioneering developer of personalized cancer vaccines utilizing its DCVax® dendritic cell platform. The company's most advanced candidate, DCVax®-L, has completed a Phase III trial for glioblastoma (GBM) and represents a significant potential advancement in a difficult-to-treat cancer. While navigating a challenging financial and regulatory path, the company is expanding its manufacturing capabilities in the UK and advancing earlier-stage programs for other solid tumors. Its long-term success hinges on securing regulatory approvals, establishing commercial manufacturing, and demonstrating its platform's efficacy beyond GBM.

View full company profile

Therapeutic Areas

Oncology Glioblastoma Solid Tumors

Other Glioblastoma (GBM) Drugs

Drug	Company	Phase	Status
DB102 (Enzastaurin)	Denovo Biopharma	Phase 3	Active
GlioGuard Therapeutic & Diagnostic System	GlioGuard	Pre-clinical	Active
DOC1021	Diakonos Oncology	Phase 2	Active
Lead CAR-T Program	Kiragen Bio	Pre-clinical	Active
GBM Immunotherapy (with SandboxAQ)	iOncologi	Pre-clinical	Active
Lucicebtide (ST101)	Sapience Therapeutics	Phase 2	Active
Glioblastoma Assay Optimization (CPRIT Grant)	SingleCell Biotechnology	Pre-clinical	Active
Lead Program (unspecified)	BlueHaven Therapeutics	Preclinical	Active
TLX101 (Pixclara® / 131I-IPA)	Telix Pharmaceuticals	Phase 3	Active (IPAX-2)
Paxalisib	Kazia Therapeutics	Phase II/III	Active